Open AccessPhase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma
Author(s) -
Elisabet E. Manasanch,
Jatin J. Shah,
Hans C. Lee,
Donna M. Weber,
Sheeba K. Thomas,
Behrang Amini,
Jasper Olsem,
Brandon N. Crumpton,
Ashley Morphey,
Zuzana Berkova,
Lei Feng,
Robert Z. Orłowski
Publication year - 2019
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2019.225375
Subject(s) - carfilzomib , panobinostat , dexamethasone , multiple myeloma , medicine , refractory (planetary science) , oncology , lenalidomide , biology , genetics , gene , histone deacetylase , astrobiology , histone